VA-REGULA
30.4.2024 09:01:34 CEST | Business Wire | Press release
Regula 70X9 document readers were shipped to three Uber Verification Centers in Warsaw, Krakow, and Poznan, which serve as dedicated hubs where drivers submit their driver’s licenses and identification documents for thorough verification. The shipment was fulfilled by Regula’s Polish distributor, Korporacja Wschód (KW), whose forensic experts also provided special training on how to use the new devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430896042/en/
Regula document readers power the driver verification process for Uber Poland (Photo: Business Wire)
The Regula 70X9 became the core element of Uber’s mission to enhance their safety protocols. It allows Uber employees to perform a comprehensive set of checks to authenticate an ID. The reader automatically identifies the document type; reads the data in all the document zones, including the visual zone, MRZ (machine-readable zone), RFID (radio frequency identification) chips, and barcodes; and cross-compares the obtained text and graphic data. Plus, the supplied document readers are equipped with Automatic Authenticity Control technology. At its core are automated checks that swiftly assess the integrity of the provided documents, detecting any signs of forgery or alteration. All of the above features, together with integrated light sources, significantly reduce the risk of mistakenly verifying forged documents.
The current workflow carried out by Uber’s employees includes:
Step 1. Comparison of the documents provided by the driver with the documents uploaded in the Uber application.
Step 2. Verification of Background Check Certificate.
Step 3. Authenticity verification of passport/ID and driver’s license with the Regula 70X9 reader.
Step 4. Taking a driver’s profile picture.
Step 5. Finalizing verification in the system: data input, document upload, and profile picture upload.
“The process of personally vetting drivers has been, and continues to be, a major logistical challenge, but we believe our efforts will help improve safety in transit. Thanks to the Regula device, the first stage went very smoothly for us. This process, although lengthy, is certainly effective,” says Marcin Konrad Moczyrog, Director and Global Manager at Uber Rides, Central & Eastern Europe.
Prior to the integration of the Regula 70X9, drivers’ documents were verified by Uber’s employees, either manually or via an application based on AI algorithms. The old method had two problems: it was time-consuming, and it did not guarantee protection against high-level forgeries of documents.
“Document fraud is constantly on the rise, and since counterfeited documents are becoming more sophisticated, manual checks are no longer enough. Some inherent document security features may be verified only with special equipment or software solutions. We are honored that our devices have become the cornerstone for a revamped verification process at Uber, and are pleased to see that it’s bearing fruit,” says Maris Kaminskis, Executive Director at Regula Europe.
For additional information, please visit the website.
About Uber
Uber is a technology application connecting passengers and drivers that has revolutionized the way people travel. Since its inception in 2009, Uber has experienced exponential growth, expanding its operations to numerous cities worldwide. Uber operates in more than 10,000 cities across more than 71 countries, making it one of the largest ride-hailing platforms globally.
In Poland, Uber is available in 25 locations.
About Korporacja Wschód
Founded in 1995, Korporacja Wschód is a family-run business that has continually evolved to meet the dynamic needs of high-technology sectors. As the distributor of Regula products in Poland since 1996, we have established ourselves as a vital link in delivering technological solutions to various enforcement and security agencies. Our expertise spans the development, integration, implementation, and distribution of advanced technology equipment, catering primarily to Border Guards, Police, Military, and a range of non-governmental enterprises and institutions. Our collaboration with Regula, a leader in forensic science technologies, underscores our commitment to offering cutting-edge solutions in document verification and security.
Learn more at https://korporacjawschod.pl.
About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed.
Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.
Learn more at regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430896042/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
